Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Abstract Background Alpha-synuclein (α-Syn) aggregation is the primary characteristic of synucleinopathies including Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Immunotherapy targeting α-Syn has shown promising results in animal models of the disease....
Main Authors: | Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13195-020-00727-x |
Similar Items
-
Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies
by: Chao Peng, et al.
Published: (2018-01-01) -
Dementia with Lewy bodies and Parkinson’s disease dementia-two independent disorders or one clinical entity within a clinical spectrum of synucleinopathies?
by: Papuć Ewa
Published: (2020-09-01) -
Autonomic Dysfunction in α-Synucleinopathies
by: José Javier Mendoza-Velásquez, et al.
Published: (2019-04-01) -
Role of α- and β-Synucleins in the Axonal Pathology of Parkinson’s Disease and Related Synucleinopathies
by: Akio Sekigawa, et al.
Published: (2015-05-01) -
Possible Alterations in β-Synuclein, the Non-Amyloidogenic Homologue of α-Synuclein, during Progression of Sporadic α-Synucleinopathies
by: Makoto Hashimoto, et al.
Published: (2012-09-01)